On-the-Ground Perspective on Putting Decentralized Strategies in Clinical Trials

About the Episode:  In this podcast, Labcorp’s Linda Ross, Associate Director of Commercial Strategy, Decentralized Clinical Trials, brings an on-the-ground perspective to the benefit of incorporating decentralized strategies into your clinical trial approach. Having worked on multiple sides of clinical research, Ms Ross is using her experience running clinical trials via flexible approaches to discuss how, after COVID, the industry can and should continue broader applications of flexible, decentralized clinical trials.    Key Takeaways: How to convey the value of consistent DCT planning to sponsorsUnderstanding current attitudes and burdens around decentralizationThe next steps in wider adoption of flexible approaches   About the Speaker:  Linda Ross has over 20 years’ experience in the pharmaceutical industry and commenced work with Labcorp in Nov 2008 where she is currently employed as an Ass. Dir. Commercial Strategy, Decentralized Clinical Trials who is regionally based in Auckland, New Zealand.  During this time, Linda has worked in a variety of leadership positions across different therapeutic areas that have involved multiple countries in Asia Pacific as well as Americas and Canada. She has developed extensive experience in developing decentralized clinical trials strategies on projects from pre-award, during set up, as well as leading new initiatives for ongoing studies which have been faced with challenging circumstances. Her current appointment includes a focus on developing DCT strategies within AsiaPac.   For more information about disruptive innovation in clinical research, click here.